BUZZ-Natera因癌症检测获得欧盟认证而股价上涨7月9日 - ** 基因检测公司Natera(NTRA.O)股价上涨2.7%,至281.85美元
** 该公司表示,其个性化癌症检测产品Signatera已获得欧盟诊断器械法规的认证
** Signatera 用于检测治疗后可能残留的微量癌细胞,并监测癌症复发情况
** 公司表示,Signatera是首款获得该欧盟认证的实体瘤个性化残留病灶检测产品
** 该认证涵盖多种癌症的检测应用,包括胃肠道癌、肺癌、乳腺癌、皮肤癌、妇科癌症以及部分血液癌症——NTRA
** NTRA表示,该认证将有助于公司在2028年监管过渡期截止后继续向欧盟患者提供Signatera,并降低开展新临床试验的门槛
** 计入本次交易,NTRA今年迄今累计上涨22%
At the request of the copyright holder, you need to log in to view this content
LOGIN / SIGN UPDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.